Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition
Garcia-Gimenez, A.; Ditcham, J. E.; Azazi, D. M. A.; Meduri, E.; Asby, R.; Sakakini, N.; Lopez, C. K.; Narayan, N.; Beinortas, T.; Bagri, J.; Agrawal Singh, S.; Giotopoulos, G.; Murphy, M. P.; Horton, S. J.; Huntly, B.; Richardson, S. E.
Show abstract
B-cell acute lymphoblastic leukemia (B-ALL) is a leading cause of death in childhood and outcomes in adults remain dismal. There is therefore an urgent clinical need for therapies that target the highest risk cases. Mutations in the histone acetyltransferase CREBBP associate with high-risk features in B-ALL and have been implicated in chemoresistance. We performed a targeted drug screen in isogenic human cell lines, identifying a number of actionable small molecules that specifically target CREBBP-mutated B-ALL. The most potent was the BCL2 inhibitor Venetoclax, which acts through a non-canonical mechanism resulting in ferroptotic cell death. CREBBP-mutated cell lines showed differences in cell-cycle, metabolism and response to oxidative stress. Lastly, we demonstrate that small-molecule inhibition of CREBBP sensitizes B-ALL cells, regardless of genotype, to Venetoclax-induced ferroptosis in-vitro and in-vivo, providing a potential novel drug combination for broader clinical translation in B-ALL.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors 97%
- Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death. 97%
- Combinatorial immunotherapies overcome MYC-driven immune evasion 97%
Similar papers in this journal
- FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer 96%
- Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells 96%
- PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity 95%
Similar papers in this journal
Similar papers in this journal
- Folate depletion induces erythroid differentiation through perturbation of de novo purine synthesis 97%
- Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing 97%
- Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.